Entrepreneurship

CARB-X

The Growing Antimicrobial Resistance Challenge

Antimicrobial resistance (AMR) is a major threat to Public Health. According to the World Health Organization, there are an estimated 700,000 deaths worldwide each year as a result of bacterial infections. The US Center for Disease Control and Prevention (CDC) estimates that in the US alone, 23,000 people die each year from drug-resistant bacterial infections.

Global Movement to Combat Antimicrobial Resistance

CARB-X is one of the world’s largest public-private partnerships dedicated to accelerating antibacterial innovation. It has the world’s largest antibacterial pipeline focused specifically on combating drug resistant bacteria, especially Gram-negative bacteria, and it supports research projects in companies around the world. CARB-X is investing more than $500 million between 2016-2021 in the development of antibiotics and other life-saving therapeutics of all types, diagnostics, vaccines and other preventatives and devices. California Life Sciences Institute (CLSI) is a vital part of CARB-X’s network of accelerators and provides business and technical support to funded projects throughout the world.

To learn more about CARB-X and funding opportunities, please consult the CARB-X website at https://carb-x.org/

We would be happy to answer your questions about CARB-X and share more ways you can get involved.
Julie Harness
Sr. Director
jharness@califesciences.org

Assistant Secretary for Preparedness and Response Barda Wellcome Trust NIH NIAID
California Life Sciences Institute Mass Bio Boston University RTI Broad Institute